BioSpace News Archive

Premier Inc., through its ProvideGx™ program, has partnered with Hikma Pharmaceuticals PLC to supply amiodarone and sterile water to healthcare providers, helping to stabilize the long-term supply of two medications vital for COVID-19 patient care.

Genome BC is pleased to announce $1 million in funding to Sonic Incytes Medical Corp., completing the company’s seed financing round of over CDN$3.5 million supported by institutional investors, angel funds and private individuals.

I-MED Pharma Inc., a Canadian medical device company, announced today that it is collaborating with KMG International Limited to manufacture and supply personal protective equipment (PPE) and COVID-19 diagnostic tests to help respond to the urgent need for these products in Canada, the United States, and Europe.

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management team will participate in several upcoming virtual investor conferences held in June 2020. Jefferies Virtual Healthcare Conference 2020 Date: June 2-

Beckman Coulter Life Sciences today announced RNAdvance Viral XP has been added to the list of acceptable extraction methods for use in the Centers for Disease Control’s EUA-authorized COVID-19 test referenced in the FDA’s FAQ on testing for SARS-CoV-2

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Quest Diagnostics Self-collection Kit for COVID-19 (self-collection kit)

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 10. Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals will represent the Company in a session scheduled at 11:20 a.m. (Eastern Time).

Part of the Foundation’s $100 million global COVID-19 relief initiative, grants focus on U.S. community response and health care in Europe and Africa.

The Management Board of Selvita S.A., one of the largest preclinical contract research organizations in Europe, has established the issue price of the C Series shares currently offered through prospectus-free Follow-On public offering, at PLN 38.

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the initiation of an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine (sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital (NCT04400929).